MindMed (MNMD stock) announces first dosing of LSD drug in phase 2b trial

MindMed begins phase 2b study of LSD treatment.
MNMD stock surged 36% on August 18.
Shares of the small-cap added 9% on Wednesday.

Clay Webster FXStreet

MindMed (MNMD) announced early Thursday that it had begun its phase 2b trial for its Generalized Anxiety Disorder (GAD) drug MM-120. Shares of the psychedelic biotech star remained flat, however, at $0.87.

MindMed stock news

The MM-120 drug utilizes a form of LSD (lysergic acid diethylamide) to treat patients with brain disorders. The current trial is meant to find the optimal dosage for patients.

MNMD shares entered the news last week and led to a surge in the stock price when USC student Jake Freeman, who achieved overnight fame after profiting some $110 million on Bed Bath & Beyond's (BBBY) meme stock surge, said he was working in tandem with his uncle to build a position in MNMD shares. His uncle, Dr. Scott Freeman, was one of the founders of a company that was acquired a decade ago by MindMed and then became the latter's chief medical officer for a year. The elder Freeman said he thought the company should push stronger for a stage 3 trial with the Food & Drug Administration (FDA).

"The initiation of our Phase 2b clinical trial, the largest well-controlled clinical trial of LSD ever conducted, represents a major milestone for MindMed and for the many patients suffering from GAD," said Robert Barrow, CEO of MindMed.

"This exciting next step in the advancement of LSD builds on the positive topline data presented by our partners at University Hospital Basel in May 2022, which demonstrated the rapid, durable, and statistically significant effects of LSD and its potential to safely mitigate symptoms of anxiety and depression. The results of our Phase 2b trial will guide the dose selection and development strategy for our pivotal Phase 3 clinical trials, as we continue our efforts to bring a new potential treatment to the millions of people living with GAD."

MindMed stock forecast

MNMD stock gained 9.1% on Wednesday after completing a quick swing high that began last Thursday. That session saw a 36% gain followed by a -17% loss on Friday. Earlier this week MNMD appears to have found support around $0.77. Another gyration could send MNMD back to Thursday's resistance zone between $1.19 and $133.

Last week's swing high demonstrated the ability to overtake early June's recent swing high, but the rapid sell-off may have scared away a large swath of penny stock traders. One good sign is that MindMed stock remains above the 9-day moving average, so this rally may not have given up yet.

MNMD stock frenzy continues on LSD drug approval

MNMD daily chart

Author

Clay Webster

FXStreet

Clay Webster grew up in the US outside Buffalo, New York and Lancaster, Pennsylvania. He began investing after college following the 2008 financial crisis.

AUD/USD rises to 0.6950 as USD slips on Fed's Warsh

AUD/USD regains traction and extends the bounce toward 0.6950 in the Asian session on Friday. Fed Chair Warsh's comments reinforce the selling pressure on the US Dollar, allowing the pair to stretch higher. Warsh said that he remains committed to delivering price stability without giving away anything on future interest rate path.

USD/JPY falls in symc with USD, gives up 158.00 after Warsh's speech

USD/JPY has come under fresh selling pressure and gives up 158.00 in the Asian session on Friday amid the emergence of fresh US Dollar selling. Fed Chair Warsh's non-committal commentary on the future tightening path, weighs on the US Dollar and the pair.

Gold looks vacillating above $4,150

Gold alternates gains with losses below the key $4,200 mark per troy ounce on Friday. The yellow metal’s irresolute price action comes in response to a modest pullback in the US Dollar and a tepid recovery in US Treasury yields across the board.

Bitcoin steadies at $82,000: The five forces crushing the Uptober rally

Crypto markets have remained under pressure so far in October, with Bitcoin (BTC) sliding below $80,000 earlier this week before recovering to around $82,000 on Friday, as macroeconomic headwinds and cooling demand weigh on the market.

The Fed just got a second hot inflation number. Here's what the diesel signal is really saying

The Federal Reserve (Fed) faces a renewed inflation challenge after two consecutive reports showed price pressure intensifying across the US economy. September's Consumer Price Index (CPI) confirmed accelerating consumer inflation, while the Producer Price Index (PPI) revealed an even sharper rise in business costs. Behind both reports lies a common factor: energy prices.

Everyone's dumping Gold after hot US inflation. Here's why $4,100 could be a floor, not a cliff

Gold (XAU/USD) is recovering from a sharp sell-off triggered by hotter-than-expected United States (US) inflation data released on Wednesday. The precious metal briefly plunged toward $4,073 as investors increased their bets on further Federal Reserve (Fed) interest rate hikes before recovering as US Treasury yields and the US Dollar (USD) reversed their initial gains.